Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
1d
Fintel on MSNLeerink Partners Downgrades 10x Genomics (TXG)Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
Request To Download Free Sample of This Strategic Report @ Highlighted with 39 tables and 46 figures, this 120-page report Asia Pacific Transcriptomics Market 2021-2031 by Component (Instruments, ...
Request To Download Free Sample of This Strategic Report @ Highlighted with 42 tables and 37 figures, this 121-page report Europe Transcriptomics Market 2021-2031 by Component (Instruments, ...
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results